Korea Signals Continued Policy Support For Pharma In 2018
Executive Summary
Despite the regime change, South Korea remained generally supportive of the pharma and biotech industry in 2017. With comprehensive long-term plans proposed to nurture these sectors, the government appears poised to pursue its favorable stance towards industry in the coming year.
You may also be interested in...
Korea Unveils 5-Year Roadmap To Nurture Domestic Industry
South Korea’s five-year blueprint to nurture the pharma industry outlines a string of measures including plans to set up smart clinical trial platforms, use artificial intelligence for new drug R&D, invest in public purpose pharma R&D and improve drug approval and reimbursement systems.
Tagrisso Reimbursed In Korea, After Difficult Price Negotiations
Korea's National Health Insurance Service and AstraZeneca reach an agreement on reimbursement of Tagrisso, sharply reducing financial burdens of NSCLC patients in the country. Tough price negotiations between the two sides underlines the difficulties pricey innovative drugs face to get reimbursed in the country.
Korea’s Biotech Roadmap Aims To Bridge Funding Gaps
South Korea reaffirms its supportive policy stance for the biotech industry with a new long-term roadmap. The plan covers the entire cycle of drug development, including R&D support to tackle the industry’s ‘valley of death’ and creation of a mega fund to help companies enter global markets.